Images List Premium Download Classic

Rheumatoid Arthritis

Rheumatoid Arthritis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8...
Abbvie Inc.
May 24, 2018 - N°20180141955

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. .
NEW Fused heteroaromatic pyrrolidinones
May 24, 2018 - N°20180141951

And pharmaceutically acceptable salts thereof, wherein g, l1, l2, r1, r2, r3, and r4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., ...
Inhibition of gliadin peptides
Alba Therapeutics Corporation
May 17, 2018 - N°20180134750

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental ...
Mitochon Pharmaceuticals, Inc.
May 10, 2018 - N°20180125794

A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, huntington's disease, epilepsy, multiple sclerosis (ms), lupus, type-1 and type-2 diabetes, maturity onset diabetes of the young (mody), myasthenia gravis (mg), rheumatoid arthritis (ra), graves' disease, guillain-barré syndrome (gb s), metabolic syndrome, muscular dystrophy or duchenne ...
Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity
The Methodist Hospital
May 03, 2018 - N°20180117176

Porous silicon (psi) microparticles (psm) are disclosed, which provide an important advance in the area of cancer immunotherapeutics and molecular nanomedicine. In particular, potent psm-based adjuvants are disclosed for dendritic cell-based vaccines compositions, and methods for their use in a variety of cancer immunotherapies.
Covalent conjugates of bet inhibitors and alpha amino acid esters
Glaxosmithkline Intellectual Property Development Limited
May 03, 2018 - N°20180117165

The present invention relates to covalent conjugates of bet inhibitors and alpha amino acid esters, processes for their preparation, compositions containing them, and to their use in the treatment of various disorders in particular inflammatory and autoimmune diseases, such as rheumatoid arthritis; and cancers.. .
Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Organic compositions to treat epas1 - related diseases
Arrowhead Pharmaceuticals, Inc.
April 12, 2018 - N°20180100151

The present disclosure relates to methods of treating epas1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and ...
Quinazoline derivatives as vegf inhibitors
Genzyme Corporation
April 12, 2018 - N°20180099946

The invention relates to quinazoline derivatives of formula (i), wherein m is an integer from 1 to 3; r1 represents halogeno or c1-3alkyl; x1 represents —o—; r2 is selected from one of the following three groups: 1) c1-5alkylr3 (wherein r3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, c1-4 alkyl, ...
Antibodies to il-6 and use thereof
Alderbio Holdings Llc
April 05, 2018 - N°20180092999

The present invention is directed to therapeutic methods using il-6 antagonists such as an ab1 antibody or antibody fragment having binding specificity for il-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum ...
Pyrazolothiazole compound and medicine comprising same
April 05, 2018 - N°20180092919

The compound of the invention has jak1 inhibitory activity, and thus, immunosuppressive effect, anti-inflammatory effect and anti-proliferative effect, and is useful in the treatment of the diseases, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis and vasculitis, bronchial asthma, chronic obstructive pulmonary disease and eosinophilic sinusitis, nasal polyp.. .
Ligands that bind tgf-beta receptor ii
Glaxo Group Limited
March 29, 2018 - N°20180086835

The disclosure provides an anti-tgfbetarii immunoglobulin single variable domain. Suitably, an anti-tgfbetarii immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of seq id no:1-28 having up to 5 amino acid substitutions, deletions or additions.
Ebna1 inhibitors and their method of use
The Wistar Institute Of Anatomy And Biology
March 29, 2018 - N°20180086699

Pharmaceutical compositions of the invention comprise ebna1 inhibitors useful for the treatment of diseases caused by ebna1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise ebna1 inhibitors useful for the treatment of diseases caused by latent epstein-barr virus (ebv) infection.
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
Rigel Pharmaceuticals, Inc.
March 15, 2018 - N°20180072756

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple ...
Rheumatoid Arthritis Patent Pack
Download 109+ patent application PDFs
Rheumatoid Arthritis Patent Applications
Download 109+ Rheumatoid Arthritis-related PDFs
For professional research & prior art discovery
inventor
  • 109+ full patent PDF documents of Rheumatoid Arthritis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody
Dnx Biotech, Llc
March 08, 2018 - N°20180066049

Tumor necrosis factor-α (tnfα) promotes an inflammatory response resulting in many clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Dysregulation of tnf production is implicated in a variety of human diseases including alzheimer's disease, cancer, major depression, and inflammatory bowel disease.
Anti-il-6 antibodies for the treatment of arthritis
Alderbio Holdings Llc
March 08, 2018 - N°20180066046

The present invention is directed to therapeutic methods using il-6 antagonists such as anti-il-6 antibodies and fragments thereof having binding specificity for il-6 to prevent or treat rheumatoid arthritis.. .
Compounds targeting proteins, compositions, methods, and uses thereof
Biotheryx, Inc.
March 08, 2018 - N°20180065952

The present invention provides modulators of protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses.
Thiazoles as modulators of roryt
March 08, 2018 - N°20180064690

The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of formula i..
Il-17 antibody formulation
Eli Lilly And Company
March 01, 2018 - N°20180057584

The present invention provides pharmaceutical formulations for anti-il-17 antibodies. These anti-il-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing psoriatic arthritis or multiple myeloma..
Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8...
Abbvie Inc.
March 01, 2018 - N°20180057502

The present disclosure relates to processes for preparing (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyppyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.. .
Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
March 01, 2018 - N°20180055791

Activation of 5-ht2a receptors using agonists at surprisingly low concentrations was shown to potently inhibit tnf-α-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (r)-doi, even many hours after treatment with tnf-α.
Antifungal treatment of rheumatoid arthritis
Gerbe Labs Inc.
February 22, 2018 - N°20180050033

Methods of treating disorders with a combination of antifungals is provided. The methods include topically administering a combination of antifungal agents to an affected tissue are provided.
Loading